Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Interest & Investment Income: 2022-2025

Historic Interest & Investment Income for Foghorn Therapeutics (FHTX) over the last 4 years, with Sep 2025 value amounting to $2.0 million.

  • Foghorn Therapeutics' Interest & Investment Income fell 41.86% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 11.65%. This contributed to the annual value of $11.9 million for FY2024, which is 9.43% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Interest & Investment Income of $2.0 million as of Q3 2025, which was down 12.00% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Interest & Investment Income peaked at $3.5 million during Q3 2024, and registered a low of $235,000 during Q1 2022.
  • For the 3-year period, Foghorn Therapeutics' Interest & Investment Income averaged around $2.7 million, with its median value being $2.7 million (2025).
  • In the last 5 years, Foghorn Therapeutics' Interest & Investment Income soared by 1,035.74% in 2023 and then plummeted by 41.86% in 2025.
  • Quarterly analysis of 4 years shows Foghorn Therapeutics' Interest & Investment Income stood at $2.4 million in 2022, then increased by 11.95% to $2.7 million in 2023, then grew by 16.39% to $3.1 million in 2024, then plummeted by 41.86% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.3 million for Q2 2025, and $2.7 million during Q1 2025.